# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## SCHEDULE 13G

Under the Securities Exchange Act of 1934

| SIGA PHARMACEUTICALS, INC  |  |                                     |  |  |  |  |
|--|--|-------------------------------------|--|--|--|--|
|  | •  | f Issuer)                           |  |  |  |  |
|  |  | N STOCK                             | -  |  |  |  |
| (Title of Class of Securities)  826917106  |  |                                     |  |  |  |  |
|  |  |                                     |  |  |  |  |
|  |  | Number)                             |  |  |  |  |
|  |  | / 10, 1998<br>                      | aic Statomont)                                   |  |  |  |
|  | (Date of Event Which Requi   | es Filling of the                   | its statement)                                   |  |  |  |
| Schedule<br>[ ] Rule<br>[X] Rule   | he appropriate box to designate is filed:<br>e is filed:<br>e 13d-1(b)<br>e 13d-1(c)<br>e 13d-1(d)                                 | te the rule purs                    | suant to which this                              |  |  |  |
|  |  |                                     |  |  |  |  |
| person's<br>securit  | mainder of this cover page sha<br>s initial filing on this form<br>ies, and for any subsequent an<br>lter the disclosures provided | with respect to<br>mendment contain | o the subject class of<br>ning information which |  |  |  |
| The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). |  |                                     |  |  |  |  |
|  | 0. 826917106   | 13G                                 | Page 2 of 5 Pages                                |  |  |  |
|  |  |                                     |  |  |  |  |
| \$<br>   | NAME OF REPORTING PERSON<br>S.S. OR I.R.S. IDENTIFICATION<br>MedImmune, Inc.<br>I.R.S. #52-1555759                                 |                                     |  |  |  |  |
|  | CHECK THE APPROPRIATE BOX IF A   | A MEMBER OF A                       | (a) [ ]<br>(b) [ ]                               |  |  |  |
| 3 5  | SEC USE ONLY   |                                     |  |  |  |  |

4 CITIZENSHIP OR PLACE OF ORGANIZATION

|     |    | State of Delaware  |         |                                      |
|-----|----|--|---------|--------------------------------------|
| _   |    | NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING                | 5       | SOLE VOTING POWER 335,530            |
|     |    | PERSON<br>WITH   |         |                                      |
|     |    |  | 6       | SHARED VOTING POWER                  |
|     |    |  |         | -0-                                  |
|     |    |  | 7       | SOLE DISPOSITIVE POWER               |
|     |    |  |         | 335,530                              |
|     |    |  | 8       | SHARED DISPOSITIVE<br>POWER<br>-0-   |
| - 9 | 9  | AGGREGATE AMOUNT   | BENEFIC | IALLY OWNED BY EACH REPORTING PERSON |
|     |    | 335,530  |         |                                      |
| - : | 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |         |                                      |
| -   | 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9                      |         | NTED BY AMOUNT IN ROW 9              |
| _   |    | 5.3%   |         |                                      |
|     | 12 | TYPE OF REPORTING  |         |                                      |
|     |    |  |         |                                      |

Item 1(a) NAME OF ISSUER SIGA Pharmaceuticals, Inc. Item 1(b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICE 666 Third Avenue New York, New York 10017 Item 2(a) NAME OF PERSON FILING MedImmune, Inc. Item 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE 35 West Watkins Mill Road Gaithersburg, Maryland 20878 Item 2(c) CITIZENSHIP Delaware Item 2(d) TITLE OF CLASS OF SECURITIES Common Stock Item 2(e) CUSIP NUMBER 826917106 Item 3 IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b), CHECK WHETHER THE PERSON FILING IS A: (a) [ ] Broker or Dealer registered under Section 15 of the Act (b) [ ] Bank as defined in Section 3(a)(6) of the Act Insurance Company as defined in Section (c) [ ] 3(a)(19) of the Act (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (e) [ ] An Investment Adviser in accordance with Section 240.13d-1(b)(1)(ii)(E)(f) [ ] An employee benefit plan or endowment

(g) []

fund in accordance with Section 240.13d-1(b)(1)(ii)(F)

person in accordance with Section 240.13d-1(b)(ii)(G)

(h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act

A parent holding company or control

- (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940
- (j) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J)

If this Statement is filed pursuant to Section 240.13d-1(c), check this box. [X]

#### Item 4 OWNERSHIP

(see cover page)

### Item 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

Item 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not applicable

Item 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not applicable

Item 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

Not applicable

Item 9 NOTICE OF DISSOLUTION OF GROUP

Not applicable

### Item 10 CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 23, 1998

MEDIMMUNE, INC.

By: /s/DAVID LEBUHN

Name: DAVID LEBUHN Title: TREASURER